rAd5 env B

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

CompletedNCT01095224

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2010-09-30End: 2016-02-29Updated: 2021-10-15

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

CompletedNCT01479296

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2011-12-31End: 2017-11-27Updated: 2021-10-15

Related Papers

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083

The Journal of Infectious Diseases2015-10-1525 citations